Comparing New Platinum Complexes for Cancer Treatment
Author Information
Author(s): T. Matsumoto, K. Endoh, K. Akamatsu, K. Kamisango, H. Mitsui, K. Koizumi, K. Morikawa, M. Koizumi, T. Matsuno
Primary Institution: Exploratory Research Laboratories, Chugai Pharmaceutical Co. Ltd.
Hypothesis
The study aims to compare the antitumour effects and nephrotoxicity of two new platinum complexes.
Conclusion
DWA2114R shows effective antitumour activity with no nephrotoxicity, unlike its isomer DWA2114S.
Supporting Evidence
- DWA2114R showed no increase in blood urea nitrogen levels, indicating lower nephrotoxicity.
- DWA2114S resulted in significant increases in urinary protein and sugar, indicating nephrotoxicity.
- Both compounds were effective against murine tumors L1210 and Colon 26.
- DWA2114R had a higher increase in life span compared to DWA2114S.
- Renal platinum concentration was more than 5-fold higher in DWA2114S-treated mice than in DWA2114R-treated mice.
Takeaway
Two new cancer drugs were tested to see which one is better at fighting tumors without hurting the kidneys. One drug was better at this than the other.
Methodology
The study involved administering two platinum complexes to mice and measuring their effects on tumors and kidney health.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Male BDF and CDF mice, 6-8 weeks of age.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website